Primary graft dysfunction in lung transplantation: still a thorn in the side of lung transplant
Kwun Hung Max Wong,Kuan Yew Michael Hsin
DOI: https://doi.org/10.21037/jtd-23-1618
2024-02-01
Journal of Thoracic Disease
Abstract:Kwun Hung Max Wong 1 , Kuan Yew Michael Hsin 2^ 1 Department of Cardiothoracic Surgery, Queen Mary Hospital, Hong Kong, China; 2 Department of Surgery, University of Hong Kong, Hong Kong, China ^ ORCID: 0000-0001-7006-4382. Comment on: Toyoda T, Cerier EJ, Manerikar AJ, et al . Recipient, donor, and surgical factors leading to primary graft dysfunction after lung transplant. J Thorac Dis 2023;15:399-409. Keywords: Primary graft dysfunction (PGD); lung transplant; chest X-ray; ex vivo lung perfusion (EVLP); cross circulation Submitted Oct 21, 2023. Accepted for publication Dec 12, 2023. Published online Jan 09, 2024. doi: 10.21037/jtd-23-1618 Lung transplant is the ultimate option for patients with end-stage lung failure who are refractory to medical therapy. The International Society of Heart and Lung Transplantation (ISHLT) reported that in the year 2019, almost 5,000 cases of lung transplants were performed (1). Primary graft dysfunction (PGD) is a clinical syndrome that develops within the first 72 hours after lung transplant that resembles adult respiratory distress syndrome (ARDS). Prior to 2005, PGD was also referred to as ischemia-reperfusion injury, noncardiogenic pulmonary edema, early graft failure, primary nonfunction of the lung, reimplantation oedema, acute lung injury and post-transplant ARDS (2). PGD is a major cause of early mortality and morbidity and decreased long-term survival following lung transplantation (3,4) with a reported incidence ranging from 10–25% (5,6). Multiple risk factors are known to increase the risk of PGD, such as donor smoking history, donor age, recipient pulmonary arterial hypertension, obesity, use of cardiopulmonary bypass, single lung transplant, higher fraction of inspired oxygen (FiO 2 ) during reperfusion and prolonged ischemic time (5,7-9). In 2005, the ISHLT Working Group proposed a standardized grading system for PGD (10). This was based on the evaluation of the partial pressure of arterial oxygen (PaO 2 )/FiO 2 (P/F) ratio O 2 and whether there are bilateral infiltrates on chest X-ray. These assessments are carried out at the time-points 6, 24, 48, and 72 hours after the operation. This was subsequently updated in 2016 to address limitations of the original 2005 consensus, and incorporated new parameters, specifically regarding the roles of extracorporeal membrane oxygenation (ECMO), high flow oxygen and pulmonary vasodilators. The absence of pulmonary edema on chest radiograph is classified as PGD 0, regardless of the P/F ratio (11). The various events involved in lung transplantation from preoperative donor management and procurement, to reperfusion can lead to the development of PGD. These include various insults to the donor lung such as ischemia, microtrauma from handling of the lung during organ explant, method of donor organ preservation, the surgical strategy of organ implantation such as single versus double lung transplant, the use and type of intraoperative circulatory support, and reperfusion. The key pathological hallmarks of PGD are ischemic injury of the pulmonary vasculature, altered permeability of the pulmonary vessels, and diffuse alveolar injury. The exact pathogenesis of PGD is not fully known, however ischemia reperfusion injury is thought to play a major role. The development of PGD represents an interplay between baseline donor and recipient factors, and a proinflammatory cascade that begins at the time of reperfusion. PGD occurs in two phases: an early phase where donor lung macrophages and lymphocytes play important roles, and a later phase which is regulated by recipient neutrophils and lymphocytes. Proinflammatory factors, including free radicals, reactive oxygen species (ROS), cytokines and neutrophilic inflammation are critical to the development of PGD. The recipient inflammatory environment also plays a crucial role in the development of PGD post-transplant (12). The development of PGD is associated with poor outcomes. These include prolonged intensive care unit (ICU) stay and mechanical ventilation, and increased use of ECMO. Post lung transplant mortality at 90 day is up to 37%, and at 1 year, is up to 34%. The long-term outcome following lung transplant is also negatively affected by PGD. The reported survival rates are 72.8%, 43.9% and 18.7% at 1, 5 and 10 years postoperatively for patients with PGD. PGD is also linked to chronic lung allograft dysfunction (CLAD), a form of chronic lung rejection. The severity of PGD is directly correlated to an increase in the relative risk of bronchiolitis obliterans syndrome, one of the forms of CLAD (12-14). In this issue of the journal, Toyoda et al. looked at risk factors (donor, recipient or intraoperative) that show an association with mild/moderate or severe PGD (15). Retrospective -Abstract Truncated-
respiratory system